文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

药物代谢酶基因多态性与抗癌药药代耐药及毒性综述

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.
PubMed 文献 · Clin Pharmacokinet · 2022-09-30

该综述从药物基因组学角度讨论药物代谢酶基因多态性如何影响抗癌药的药代动力学耐药与毒性。文中举例CYP1B1*3与紫杉类/铂类耐药相关,496T>G与二氢嘧啶脱氢酶降低及5-氟尿嘧啶严重毒性相关。作者认为药物基因组学方法有助于实现安全有效且避免耐药的个体化用药。

要点

  • 药物代谢酶基因多态性可影响抗癌药药代动力学,导致耐药或毒性。
  • CYP1B1*3与CYP1B1过表达及紫杉类、铂类耐药相关。
  • 496T>G与二氢嘧啶脱氢酶降低及5-氟尿嘧啶严重毒性相关。

核心结论

  • 药物代谢酶基因多态性可影响抗癌药的药代动力学特征,进而导致药代动力学耐药或毒性。
  • 药物基因组学方法可综合药理学与基因组学,用于开发安全有效且避免耐药问题的药物。

研究设计与样本

  • 本文为综述,讨论药物代谢酶多态性在抗癌药药代动力学耐药与毒性中的药物基因组学作用。

主要发现

  • CYP1B1*3等位基因与CYP1B1过表达及对多种紫杉类和铂类的耐药相关。
  • 496T>G与二氢嘧啶脱氢酶水平降低相关,导致5-氟尿嘧啶相关严重毒性。
  • 近期基因组学研究揭示了肿瘤中许多单核苷酸多态性的影响,并强调药物代谢酶单核苷酸多态性对抗肿瘤药物作用的重要性。

临床怎么用

  • 对接受化疗的癌症患者,可考虑基于药物代谢酶基因信息进行个体化用药,以避免药代动力学耐药或毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The inter-individual differences in cancer susceptibility are somehow correlated with the genetic differences that are caused by the polymorphisms. These genetic variations in drug-metabolizing enzymes/drug-inactivating enzymes may negatively or positively affect the pharmacokinetic profile of chemotherapeutic agents that eventually lead to pharmacokinetic resistance and toxicity against anti-cancer drugs. For instance, the CYP1B1*3 allele is associated with CYP1B1 overexpression and consequent resistance to a variety of taxanes and platins, while 496T>G is associated with lower levels of dihydropyrimidine dehydrogenase, which results in severe toxicities related to 5-fluorouracil. In this context, a pharmacogenomics approach can be applied to ascertain the role of the genetic make-up in a person's response to any drug. This approach collectively utilizes pharmacology and genomics to develop effective and safe medications that are devoid of resistance problems. In addition, recently reported genomics studies revealed the impact of many single nucleotide polymorphisms in tumors. These studies emphasized the importance of single nucleotide polymorphisms in drug-metabolizing enzymes on the effect of anti-tumor drugs. In this review, we discuss the pharmacogenomics aspect of polymorphisms in detail to provide an insight into the genetic manipulations in drug-metabolizing enzymes that are responsible for pharmacokinetic resistance or toxicity against well-known anti-cancer drugs. Special emphasis is placed on different deleterious single nucleotide polymorphisms and their effect on pharmacokinetic resistance. The information provided in this report may be beneficial to researchers, especially those who are working in the field of biotechnology and human genetics, in rationally manipulating the genetic information of patients with cancer who are undergoing chemotherapy to avoid the problem of pharmacokinetic resistance/toxicity associated with drug-metabolizing enzymes.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Narendra G, Choudhary S, Raju B, et al. Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect. Clin Pharmacokinet. 2022. PMID: 36180817. doi:10.1007/s40262-022-01174-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。